Bellerophon Therapeutics, Inc. (BLPH)

Bellerophon Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Market Capitalization	1	9	29	52	24	52
Market Cap Growth	-53.25%	-70.82%	-43.36%	119.97%	-54.64%	-48.13%
Enterprise Value	-4	2	6	6	16	35
PE Ratio	-	-0.43	-1.66	-2.10	-1.78	18.52
PS Ratio	0.11	-	-	-	-	-
PB Ratio	0.17	3.39	1.36	1.36	6.58	13.52
P/FCF Ratio	-0.39	-0.48	-1.29	-2.62	-1.83	-3.36
P/OCF Ratio	-0.39	-0.48	-1.29	-2.62	-1.83	-3.36
EV/Sales Ratio	0.09	-	-	-	-	-
EV/EBITDA Ratio	-0.04	-0.08	-0.27	-0.23	-0.81	-0.68
EV/EBIT Ratio	-0.04	-0.08	-0.27	-0.23	-0.80	-0.67
EV/FCF Ratio	-0.04	-0.11	-0.25	-0.31	-1.24	-2.29
Debt / Equity Ratio	0	0.08	0.04	0.04	0.65	0
Debt / EBITDA Ratio	-	-0.01	-0.05	-0.06	-0.12	-
Debt / FCF Ratio	-	-0.01	-0.04	-0.08	-0.18	-
Quick Ratio	3.49	1.28	4.90	4.56	1.30	2.21
Current Ratio	3.96	1.40	5.04	4.61	1.37	2.31
Asset Turnover	0.35	0	0	0	0	0
Interest Coverage	0	-165.81	-4032.20	-105.10	0	0
Return on Equity (ROE)	-313.46%	-782.60%	-82.13%	-64.65%	-369.45%	72.98%
Return on Assets (ROA)	-234.38%	-249.92%	-66.07%	-49.22%	-101.21%	15.33%
Return on Capital (ROIC)	-296.40%	-817.83%	-89.31%	-65.84%	-295.75%	-723.03%
Earnings Yield	-1870.60%	-230.71%	-60.27%	-47.55%	-56.11%	5.40%
FCF Yield	-1977.84%	-206.73%	-77.47%	-38.23%	-54.71%	-29.73%
Buyback Yield / Dilution	-28.15%	-0.51%	-21.88%	-73.14%	-3.85%	-67.00%
Total Shareholder Return	-28.15%	-0.51%	-21.88%	-73.14%	-3.85%	-67.00%

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.